Our Journey
Headquartered in the USA with subsidiaries in India and Australia. We have discovered novel dual target acting microbial agents now in clinical trials.
Over the years, we have diversified our expertise in the areas of cancer biology and immunology.
Bugworks is developing novel class of broad-spectrum antibacterial agents and immunotherapies to treat patients with critical care needs in infection and cancer.
News & Announcements
From Cells to Molecules to Products – an in-depth video on CCAMP done by Pallava Bala for India Science. Bugworks is one of the six companies to be highlighted.
December 15, 2021 Published in Indiascience.com
Bugworks Research Inc. CSO Dr. Santanu Datta underscores need for a Bayh-Dole like Act to propel research commercialization
November 15, 2021 Published in Pharmabiz.com
Bugworks Research starts first human dose study to treat critical bacterial infections – ETHealthWorld
November 10, 2021 Published in ETHealthworld.com
Bugworks Research begins first in human phase 1 study of BWC0977 to treat critical bacterial infections
November 9, 2021 Published in Pharmabiz.com
Our Story
